49,983 Shares in Celularity, Inc. $CELU Bought by Valmark Advisers Inc.

Valmark Advisers Inc. bought a new position in Celularity, Inc. (NASDAQ:CELU) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 49,983 shares of the company’s stock, valued at approximately $98,000. Valmark Advisers Inc. owned 0.21% of Celularity at the end of the most recent quarter.

Separately, Acadian Asset Management LLC purchased a new position in shares of Celularity in the 1st quarter worth $34,000. Hedge funds and other institutional investors own 19.02% of the company’s stock.

Celularity Price Performance

Shares of Celularity stock opened at $2.05 on Friday. The business has a 50-day moving average of $2.77 and a 200-day moving average of $2.28. The company has a market capitalization of $54.71 million, a PE ratio of -0.64 and a beta of 0.75. Celularity, Inc. has a 1-year low of $1.00 and a 1-year high of $5.22.

Celularity (NASDAQ:CELU) last announced its earnings results on Friday, August 29th. The company reported ($1.02) earnings per share for the quarter. The business had revenue of $5.74 million for the quarter. Celularity had a negative net margin of 165.22% and a negative return on equity of 459.57%.

Analysts Set New Price Targets

CELU has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celularity in a research report on Wednesday. WBB Securities raised Celularity from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a research report on Tuesday, September 9th. Finally, Wall Street Zen lowered Celularity from a “hold” rating to a “sell” rating in a research report on Friday, September 5th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Celularity presently has an average rating of “Hold” and an average target price of $6.00.

Celularity Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.